One issue I see JBeez, RAC isn't currently pursuing mBC...We...

One issue I see JBeez, RAC isn't currently pursuing mBC...

We can't produce a current NPV as we've no idea on what the FDA will require (trial wise) for CPACS (Zan + Dox) in solid tumours broadly, and therefore forecasting costs through to registration is a massive thumb suck.

I try not to get too caught up in what a reasonable present valuation might be, but focus on the opportunity at large, and try and determine the likelihood of success. For instance, extrapolating the Triangle report data; if Zan captures just 1% of the global CPACS Zan+Dox synergy opportunity, ballpark peak revenue looks to be ~US$3.4B.

IMO, what holders should be considering now; what does a third party consider our likelihood of success, and what is a regional licensing deal worth to them? Astex have agreed to free issue RAC with Inqovi, so they can't consider our chance of success 0...